Apoptosis is a widely accepted component of the pathogenesis of Parkinson's disease (PD), a debilitating neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra. However, additional death programs were implicated, and current understanding of the cycle of intracellular events that leads to the demise of these neurons is limited. Gene therapy strategies were proposed to inhibit apoptosis, but they have met with relatively limited success. Here we report that the antiapoptotic herpes simplex virus type 2 gene ICP10PK protects neuronally differentiated PC12 cells from death caused by 1-methyl-4-phenylpyridinium (in vitro PD model) through inhibition of calpain I activation and the resulting inhibition of Bax translocation to the mitochondria, apoptosis-inducing factor release and caspase-3 activation. Neuroprotection is through ICP10PK-mediated activation of the PI3-K/Akt survival pathway and upregulation/stabilization of the antiapoptotic protein Bcl-2 and the cytoprotective chaperone heat-shock protein 70.
Introduction
Parkinson's disease (PD) is a debilitating neurodegenerative disorder that is characterized by selective loss of dopaminergic neurons in the substantia nigra. The intracellular cascade of events leading to neuronal death is still poorly understood, and appears to involve multiple death programs and inflammatory responses potentially related to microglial activation. 1 Therapeutic strategies to inhibit apoptosis were considered, but they met with relatively limited success, 2, 3 and the surviving neurons did not retain normal synaptic function. 4 Further confounding decisions about the appropriate choice of therapy, recent findings suggest that the death of dopaminergic neurons is not due to canonical apoptosis, but rather to caspase-independent programmed cell death (PCD) [5] [6] [7] [8] or necrosis. 9 Consequently, treatment is largely symptomatic rather than preventive. 10 Previous studies have shown that the herpes simplex virus type 2 (HSV-2) protein ICP10PK inhibits caspasedependent apoptosis and protects from various neurotoxic stimuli including viral infection, treatment with a protein kinase C inhibitor, disruption of osmolar environment, loss of trophic growth support and excitotoxicity. Neuroprotection was seen in cultured cells, organotypic slices and animal models, and it was through the activation of redundant survival pathways. [11] [12] [13] [14] [15] [16] Most importantly, the surviving neurons retained synaptic function, 11, 13, 14 suggesting that ICP10PK has strong and versatile neuroprotective potential that might be harnessed in the treatment of PD. However, the ability of ICP10PK to inhibit caspaseindependent PCD is still unknown. The studies described in this report were designed to address this question, using an in vitro model of PD in which neuronally differentiated PC12 cells are treated with 1-methyl-4-phenylpyridinium (MPP+). We report that ICP10PK inhibits MPP+-induced PCD by inhibiting calpain I activation and apoptosis-inducing factor (AIF) release, through activation of the PI3-K/Akt survival pathway. This is the first report that ICP10PK inhibits calpain I activation, and it underscores the therapeutic promise of ICP10PK in neurodegenerative diseases associated with multiple death programs.
Results

ICP10PK inhibits MPP+-induced toxicity
To examine whether ICP10PK inhibits MPP+-induced cell death, neuronally differentiated PC12 cells were treated with the ICP10PK vector DRR, that is neuroprotective in other toxicity paradigms, 11, [13] [14] [15] [16] [17] and exposed to MPP+ (1 mM, 24 h) at 24 h after infection. PCD was evaluated based on DNA fragmentation measured by terminal transferase dUTP nick-end labeling (TUNEL). The percent TUNEL + cells was calculated by counting five randomly selected fields (at least 250 cells, in a 3 mm 2 area) and results are expressed as percent TUNEL + cells/total cells (determined by 46-diamidino-2-phenyl indole (DAPI) staining) ± s.e.m. 11, 12, 16 The vector deleted in ICP10PK (DPK) and cells mock-infected with phosphate-buffered saline (PBS) served as control. The percent TUNEL + cells induced by MPP+ was significantly reduced by DRR (Po0.001), but not DPK, suggesting that ICP10PK inhibits MPP+-induced toxicity ( Figure 1a) . However, use of DRR does not fully exclude the possibility that HSV-2 genes other than ICP10PK may contribute to neuroprotection. Accordingly, the second series of experiments asked whether neuroprotection also occurs in PC12 cells stably transfected with ICP10PK. We used two clonal lines, one stably transfected with ICP10PK (PC47), the other stably transfected with the ICP10 kinase-negative mutant p139t (PC139). The establishment and properties of these cells were previously described 12 and are summarized in 'Materials and methods'. Neuronally differentiated PC12, PC47 and PC139 cells were mock treated with PBS or treated with MPP+ (0.5, 1 or 5 mM) and examined by TUNEL 24 and 48 h later. The percent TUNEL + cells in PC47 cultures given 5 mM MPP+ for 48 h (32 ± 5%) was significantly (Po0.001) lower than in similarly treated PC12 and PC139 cultures (72 ± 5 and 82 ± 6%, respectively; Figures 1b and c). Staining with antibody to tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis that is commonly used as a marker for functional dopaminergic neurons, 18 indicated that 69 ± 6% of the MPP+-treated PC47 cells were positive for both ICP10PK and TH, whereas the percent TH + cells was significantly lower (Po0.001) in PC12 and PC139 cultures (Supplementary Figure 1) . Collectively, the data indicate that ICP10PK protects from MPP+-induced toxicity independent of other viral genes, and the surviving neurons retain functionality. Stably transfected cells were used to examine the mechanism of neuroprotection.
ICP10PK inhibits MPP+-triggered AIF release/nuclear translocation
Both caspase-dependent [19] [20] [21] and -independent 5-7 programs were implicated in MPP+-induced toxicity. Previous studies had shown that ICP10PK overrides caspase-dependent cascades, [11] [12] [13] [14] [15] [16] [17] but its ability to inhibit caspase-independent death programs is still unknown. In a first series of experiments to address this question, neuronally differentiated PC12, PC139 and PC47 cells were treated with MPP+, exposed to the mitochondrionselective dye MitoTracker Red 580 and stained with Alexa Fluor 488-labeled AIF antibody, as described in 'Materials and methods'. MitoTracker staining (mitochondria) was seen in all cultures (Figure 2a) . In MPP+-treated PC47 cells, AIF colocalized with MitoTracker, but colocalization was not seen in similarly treated PC12 and PC139 cells, in which AIF was intranuclear and colocalized with DAPI ( Figure 2a ). This is not an artifact unique to stably transfected cells, as AIF colocalized with the mitochondria in DRR-infected PC12 cells that are protected from PCD, but not in the unprotected DPKinfected cells, in which AIF was intranuclear (Supplementary Figure 2 ).
Because recent reports have associated AIF release with calpain activation, 7, 22 we wanted to know whether ICP10PK-mediated neuroprotection is associated with calpain inhibition. Neuronally differentiated PC12, PC139 and PC47 cells were treated with MPP+ in the absence or presence of the cell-permeable calpain inhibitor calpeptin (50 mM), incubated with MitoTracker and stained with AIF antibody, as described in 'Materials and methods'. The results summarized in Figure 2a for PC12 and PC47 cells indicate that calpeptin inhibited AIF translocation to the nucleus in MPP+-treated PC12 cells. Similar results were obtained for PC139 cells (data not shown), but translocation was not seen in PC47 cells, whether in the absence or presence of calpeptin ( Figure  2a) . The cells in which AIF did not colocalize with mitochondria (for example, AIF was in the cytoplasm or nucleus) were counted in five randomly selected fields (at least 250 cells) and the percent with AIF release was calculated relative to total cell numbers determined by DAPI staining. AIF release was virtually identical in MPP+-treated PC12 and PC139 cells (60±4 and 65±6%, respectively), but it was significantly lower in MPP+-treated PC47 cells (12±2%). In PC12 and PC139 cells, release was inhibited by calpeptin (4 ± 3 and 5 ± 2% for PC12 and PC139 cells, respectively; Figure 2b ), but calpeptin had no effect on AIF release from PC47 cells (1±1%). These percentages are not an artifact due to different levels of transgene expression, because both ICP10PK and p139t are expressed in 96-100% of the cells 12 ( Supplementary Figure 1) . The data indicate that MPP+-induced AIF release is calpain dependent, and it is inhibited by ICP10PK.
To confirm that ICP10PK inhibits the MPP+-induced AIF release, cytoplasmic and nuclear fractions from neuronally differentiated PC12, PC139 and PC47 cells were obtained at 0, 4 or 24 h after treatment with MPP+ and immunoblotted with AIF antibody. A 57 kDa band, which is consistent with the released AIF protein, 22 was barely detectable in the cytoplasmic fractions from all three cell types at 0 h. Its levels were significantly higher in the cytoplasmic fractions from PC12 and PC139 cells treated with MPP+ for 4 h, preceding its nuclear translocation, which was first seen at 24 h post-treatment. The levels of AIF were not increased in the cytoplasmic fractions from MPP+-treated PC47 cells and the nuclear fractions remained free from AIF ( Figure 2c ).
AIF is a major component of MPP+-induced PCD
MPP+ caused a significant (2.5-fold) increase in the levels of AIF, but these were reduced to the baseline level when MPP+ was given together with an AIF antisense oligonucleotide (aODN) (10 mM; Figure 3a ). This reduction in the levels of AIF was associated with a significant (Po0.01) increase in cell survival (decreased percent TUNEL + cells; Figure 3c ), but increased survival was not seen in cells in which MPP+ was given with the sense oligonucleotide that did not inhibit AIF expression. The data indicate that AIF release and its nuclear translocation are important in MPP+-induced PCD, and they are inhibited by ICP10PK. ICP10PK neuroprotection in MPP+ model of PD SQ Wales et al but the p76/p80 ratio was not increased in PC47 cells, whether treated or not with calpeptin ( Figure 4a ). In PC47 cells given MPP+ together with the PI3-K inhibitor LY294002, the p76/p80 ratio was similar to that seen in MPP+-treated PC12 and PC139 cells (Figure 4b ), suggesting that ICP10PK inhibits calpain I activation through the activation of the PI3-K/Akt pathway. Calpain inhibition is a critical event in the ability of ICP10PK to inhibit MPP+-induced cell death, because the percent TUNEL + cells was reduced in PC12 and PC139 cultures treated with MPP+ in the presence of calpeptin, as compared to MPP+ treatment alone. By contrast, in PC47 cells, in which calpain I is inhibited by ICP10PK, MPP+ did not increase the percent TUNEL + cells whether in the absence or presence of calpeptin (Figure 4c ).
MPP+-induced
MPP+ triggers calpain-dependent Bax mitochondrial translocation
Because Bax was implicated in several paradigms of neuronal PCD, 6, 25 we wanted to know whether it is related to the ability of ICP10PK to inhibit MPP+-induced PCD. Neuronally differentiated PC12, PC139 and PC47 cells were treated, or not, with MPP+ in the presence or absence of calpeptin, incubated with MitoTracker and stained with fluorescein isothiocyanate (FITC)-labeled Bax antibody. The number of cells with Bax translocation (colocalization with mitochondria) was counted (five randomly selected fields,4250 cells) and the percent was calculated relative to the total cell numbers. In untreated PC12 cells, Bax was in the cytosol, but it did not colocalize with MitoTracker ( Figure 5a ). Mitochondrial translocation was seen in 63±9% of the MPP+-treated PC12 cells and it was inhibited by calpeptin (reduced to 9 ± 2%; Figures 5a and b). Similar results were obtained for PC139 cells (58 ± 3 and 7 ± 1% Bax translocation for MPP+ and MPP+ with calpeptin, respectively). By contrast, in MPP+-treated PC47 cells, in which calpain I is not activated, Bax did not colocalize with MitoTracker whether in the presence or absence of calpeptin (12 ± 2 and 10 ± 3% in MPP+ and MPP+ with calpeptin, respectively; Figure 5 ). The data indicate that MPP+ triggers calpain-dependent Bax translocation to the mitochondria and this is inhibited by ICP10PK.
MPP+ triggers calpain-dependent caspase-3 activation
The contribution of caspase activation to the death of MPP+-treated dopaminergic neurons is still controversial. 5, 7 As ICP10PK inhibits calpain activation, we wanted to know whether its neuroprotective activity is caspase independent. Neuronally differentiated PC12, PC139 and PC47 cells were treated with MPP+ or mocktreated with PBS and stained by double immunofluorescence with FITC-labeled antibody to activated caspase-3 (caspase-3p20) and Alexa Fluor 546-labeled ICP10 antibody. The caspase-3p20 staining cells were counted and the percent positive cells was calculated as described above. Caspase-3p20 staining was seen in a minimal number (B2%) of mock-treated PC12, PC139 and PC47 cells (Figures 6a and b) . MPP+ caused a small, albeit significant (Po0.01), increase in the percent staining cells in PC12 and PC139 cultures (21 ± 4 and 25 ± 6%, respectively). This increase was inhibited by calpeptin (5 ± 4 and 7 ± 2% caspase-3p20 + cells, respectively), indicating that caspase is downstream of calpain (Figures 6a-c) . Triple staining with Alexa Fluor 350-labeled ICP10 antibody, Alexa Fluor 546-labeled TH antibody and FITC-labeled caspase-3p20 antibody confirmed that most PC47 cells were negative for caspase-3p20 although evidencing ICP10PK and TH colocalization (Supplementary Figure 3) . Significantly, although caspase is a relatively minor component of the death network, downstream of calpain, it contributes to the death of PC12 and PC139 cells, as evidenced by the finding that its inhibition with ZVAD-fmk caused a 25% reduction in the percent TUNEL + cells. ZVAD-fmk had no effect on PC47 cells (Figure 6d ).
ICP10PK activates the PI3-K/Akt pathway and upregulates/stabilizes the antiapoptotic protein Bcl-2
To confirm that ICP10PK inhibits calpain I through the activation of the PI3-K/Akt survival pathway, neuronally differentiated PC12, PC139 and PC47 cells were treated with MPP+ for 0, 24 or 48 h in the presence or absence of LY294002 and examined for Akt activation by immunoblotting with antibody specific for the phosphorylated Akt (pAkt). The blots were stripped and reprobed with antibody to total Akt, used as control. Duplicate cultures treated with MPP+ in the presence of the unrelated MEK inhibitor, U0126 (20 mM), were studied in parallel and served as control. The results were quantitated by densitometry and are expressed as pAkt/Akt ratios. Low levels of pAkt were seen in all cultures at 0 h. In PC12 cells, pAkt was not seen after MPP+ treatment whether it was given with or without inhibitors. Low levels of pAkt were seen in PC139 cells, but its levels were significantly higher in MPP+-treated PC47 cells, particularly at 48 h after treatment. pAkt was inhibited by LY294002, but not U0126 (Figure 7a ), supporting the conclusion that ICP10PK activates the PI3-K/Akt pathway and the activation is kinase dependent.
Because (1) ICP10PK upregulates/stabilizes the antiapoptotic protein Bcl-2 through PI3-K/Akt activation 17 and (2) dopaminergic cell lines stably expressing Bcl-2 are protected from MPP+-induced cell death, 6 we wanted to know whether Bcl-2 is also involved in ICP10PK-mediated neuroprotection in our system. Extracts from neuronally differentiated PC12, PC139 and PC47 cells treated with MPP+ for 0, 4, 24 or 48 h were 
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immunoblotted with Bcl-2 antibody and the blots were stripped and reprobed with actin antibody. The results were quantitated by densitometry and expressed as Bcl-2/actin ratios, as described in 'Materials and methods'. Bcl-2 was expressed in all the cultures at 0 h, but expression was significantly reduced by MPP+ in PC12 and PC139 cells by 24 h after treatment. By contrast, in PC47 cells, MPP+ elicited nearly a 2.5-fold increase in Bcl-2 expression, first observed at 4 h and still seen at 48 h after treatment (Figure 7b ). Bcl-2 upregulation/ stabilization was through PI3-K/Akt activation, because it was significantly (Po0.05) reduced by treatment with LY294002, but not U0126 (Figure 7b ).
ICP10PK upregulates heat-shock protein 70
Increased expression/stabilization of the cytoprotective chaperone heat-shock protein 70 (Hsp70) was associated with inhibition of AIF release. 26 To examine whether Hsp70 is also associated with the ICP10PK neuroprotective activity, neuronally differentiated PC12, PC139 and PC47 cells treated with MPP+ for 0, 4 or 24 h were immunoblotted with Hsp70 antibody. The blots were ICP10PK neuroprotection in MPP+ model of PD SQ Wales et al stripped and reprobed with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody and protein levels were quantitated by densitometric scanning, as previously described. 12 Hsp70 was expressed in PC12 and PC139 cells, but the expression was lost (PC12 cells) or was minimal (PC139 cells) at 24 h post-treatment. Expression was significantly more robust in PC47 cells and it was retained at the same levels throughout the study interval (Figure 8b ). The data indicate that Hsp70 upregulation/stabilization is associated with ICP10PK-mediated neuroprotection.
Discussion
The salient feature of the data presented in this report is the finding that ICP10PK inhibits MPP+-induced PCD by blocking calpain I activation through the activation of the PI3-K/Akt survival pathway. Previous studies had shown that ICP10PK inhibits caspase-dependent apoptosis triggered by various neurotoxic stimuli, [11] [12] [13] [14] [15] [16] [17] 27 but this is the first report that it also inhibits calpaindependent PCD, underscoring its ability to override multiple death programs. The following comments seem pertinent with respect to these findings.
MPP+-induced neurotoxicity is an established model of PD, also in neuronally differentiated PC12 cells, 7, 9 a system we used in the present studies. We confirmed cell differentiation by neurite formation, expression of the neuronal marker microtubule-associated protein (MAP-2) and absence of 5 0 -bromo-2 0 -deoxyuridine incorporation, as previously described.
12 ICP10PK was delivered with the neuroprotective vector DRR 11,13-17 or by stable transfection of PC12 cells. 12 DPK and the cells stably transfected with the kinase-negative ICP10PK mutant p139t served as controls. The stably transfected cells were used to exclude potentially confounding variables related to viral proteins other than ICP10PK; DRR was used to exclude potentially confounding variables related to clonal line selection. MPP+ caused a dose-dependent increase in the percent TUNEL + cells in PC12 cultures as well as in cultures infected with DPK or transfected with p139t (PC139), but not in cultures that were infected with DRR or ICP10PK (PC47). The data indicate that ICP10PK protects from MPP+ toxicity independent of other viral genes and clonal cell selection, and protection is kinase dependent.
The levels of cytoplasmic AIF were increased in PC12 and PC139 cells, early after MPP+ treatment (4 h) and this was followed by its nuclear translocation, seen at 24 h after treatment, concomitant with DNA fragmentation (TUNEL). Analysis of AIF release on a cell population basis indicates that AIF was released in most of the PC12 and PC139 cells (60-65%), but the release was not seen in PC47 cells, but ICP10PK and p139t were expressed equally well and in virtually all the cells (96-100%). MPP+-induced AIF release from PC12 and PC139 cells is consistent with the results obtained by immunoblotting of nuclear and cytoplasmic fractions, which only detected its released 57 kDa protein form. 22 We conclude that AIF is involved in MPP+-induced cell death, because an antisense ODN that inhibits its expression caused a significant increase in the survival of treated PC12 and PC139 cultures, although increased survival was not seen in cultures given MPP+ together with the control (sense) ODN, which does not inhibit AIF expression. Release is due to calpain activation, as evidenced by the findings that (1) MPP+ increased the p76/p80 ratio of the calpain I forms, 24, 28, 29 and (2) both AIF release and PCD (TUNEL) were inhibited by the broad-spectrum calpain inhibitor calpeptin. Calpeptin inhibited the MPP+-induced increase in the p76/p80 ratio in PC12 and PC139 cells (data not shown), as also independently reported for its effect on p76/p80 in other systems. 24, 29 Calpain I was not activated and AIF was not released in PC47 cells in which MPP+ did not cause PCD, indicating that the neuroprotective activity of ICP10PK is through inhibition of calpain I activation. In our studies, calpeptin was used at previously established doses, 30 but other calpain inhibitors were not studied, and the possible contribution of calpains other than calpain I, to MPP+-induced toxicity is still unclear. Notwithstanding, our findings are consistent with the report that calpain I truncates AIF to its 57 kDa form, thereby causing its release from the mitochondria 22 and its subsequent translocation to the nucleus, where it interacts with DNA, stimulating the formation of a 'degradosome'. 5 Although one study attributed increased AIF release to upregulation of BimEL, 7 the predominant view is that upon commitment to apoptosis, the proapoptotic protein Bax undergoes conformational changes, oligomerizes and forms pores in the outer mitochondrial membrane that allow the release of mitochondrial factors, including AIF. 31 Our data are consistent with this interpretation. They indicate that Bax colocalized with the mitochondria in a similar proportion of MPP+-treated PC12 and PC139 cells as those showing AIF release (60-65%), and colocalization was inhibited by calpeptin. Presumably, ICP10PK neuroprotection in MPP+ model of PD SQ Wales et al calpain I activation caused Bax to translocate to the mitochondria, where it contributed to membrane permeabilization and AIF release. Indeed, Bax did not translocate to the mitochondria in PC47 cells, in which calpain I was inhibited and AIF was not released. Interestingly, caspase-3 was activated by MPP+ in a relatively small percent of PC12 and PC139 cells (23-28%) and activation was inhibited by calpeptin, indicating that caspase-3 is downstream of calpain activation. Nonetheless, the pan-caspase inhibitor ZVAD-fmk decreased the percent TUNEL + cells in MPP+-treated PC12 and PC139 cultures by an approximately similar level (25%), indicating that the contribution of caspase activation to PCD is independent of that of AIF release. MPP+-activated calpain appears to initiate both the AIF-and caspase-3-dependent death cascades, as schematically represented in Figure 9 . By inhibiting calpain activation, ICP10PK overrides the contribution of both cascades, such that neither ZVADfmk nor calpeptin had any effect on the percent TUNEL + cells in PC47 cultures.
How does ICP10PK inhibit calpain activation? We have previously shown that ICP10PK activates Ras through phosphorylation (and, thereby, inhibition) of the negative Ras regulator Ras-GAP as well as binding of the GDP/GTP exchange factor SOS (complexed to the adapter protein Grb2), thereby favoring its interaction with Ras. 32, 33 In turn, Ras activates the Raf-1/MEK/ERK and PI3-K/Akt pathways that override death cascades. In virus-infected hippocampal cultures, ICP10PK-mediated neuroprotection is through the Raf-1/MEK/ ERK pathway, 15, 16 but both MEK/ERK and PI3-K/Akt are involved in the ability of ICP10PK to protect from excitotoxic injury. 13, 17 In PC47 cells, calpain inhibition was blocked by the PI3-K inhibitor LY294002, but not the MEK inhibitor U0126, suggesting that ICP10PK overrides the calpain cascades through the activation of the PI3-K/ Akt pathway. Consistent with this interpretation, the levels of phosphorylated (activated) Akt were significantly increased in PC47 cells (susceptible to LY294002 inhibition), but not in PC12 and PC139 cells. The inhibitors used in these studies had previously been shown to block ICP10PK-mediated neuroprotection in other toxicity paradigms, and similar results were obtained for LY294002 at 100 mM, U0126 at 10 mM and the MEK inhibitor PD98059 at 25-100 mM or the PI3-K inhibitor wortmannin. 13, 15, 16, 33 PI3-K/Akt activation culminated in Bcl-2 upregulation/stabilization, 17 as evidenced by (1) significantly higher levels and prolonged duration of Bcl-2 expression in PC47 than PC12 and PC139 cells and (2) Bcl-2 reduction with LY294002, but not U0126. Hsp70 was also upregulated/stabilized in MPP+-treated PC47, but not PC12 and PC139 cells, albeit by a still unknown mechanism. We assume that this is also through PI3-K/Akt activation, because Hsp70 was not upregulated in cells in which ICP10PK-mediated neuroprotection is strictly MEK/ERK dependent 12 and other studies had shown that its upregulation is PI3-K/ Akt dependent. 34 The mechanism of Hsp70 upregulation/stabilization by ICP10PK is currently under investigation.
It is widely accepted that the MPP+ model reproduces many of the clinical and pathological hallmarks of PD, 35, 36 a widespread neurodegenerative disorder, triggered by genetic factors and environmental toxins and characterized by the loss of dopaminergic neurons in the substantia nigra. The mechanism responsible for neuronal degeneration characteristic of PD is still poorly understood and appears to involve multiple death programs. They include activation of caspases 19, 28, 37 or calpain, 7, 28 mitochondrial dysfunction and increased release of proapoptotic factors, such as cytochrome c and AIF, 5, 7 as well as Bax upregulation and its translocation to the mitochondria. 25, 35, 37 Overexpression of Bcl-2 6, 35, 38 or Hsp70 9 was shown to contribute to protection. However, the exact relationship between these potentially distinct components of the death network is still unclear, presumably contributing to difficulties in identifying an effective neuroprotective strategy. 10 Some studies attributed MPP+ toxicity to cytochrome c release from the mitochondria and the resulting activation of caspases-9 and -3, 19, 39 and showed that caspase inhibitors are neuroprotective. 20 Caspase inhibitors failed to protect in other studies 5, 6 and a caspase-independent pathway, in which AIF was released from the mitochondria and translocated to the nucleus, was shown to cause DNA fragmentation. 5, 7 Dichotomy between the findings for cell death and neurite dysfunction was also reported 21 and additional studies attributed neuronal death to both caspasedependent and -independent pathways, 6,35,40 necrosis 9 or distinct PCD pathways that involve oxidative stress, 2 or autophagy. 41 Calpains were also implicated in PD and Figure 9 Schematic representation of ICP10PK-mediated neuroprotection from 1-methyl-4-phenylpyridinium (MPP+)-induced programmed cell death (PCD). ICP10PK activates the PI3-K/Akt pathway through Ras activation, as previously described. 13, 17 The activated pathway results in upregulation/stabilization of Bcl-2. This counteracts MPP+-induced calpain I activation and subsequent mobilization of Bax to the mitochondria, apoptosis-inducing factor (AIF) release and nuclear translocation, and caspase-3 activation. ICP10PK also causes upregulation/stabilization of Hsp70, by a still unknown mechanism. Arrows represent activation, dotted arrows represent potentially involved factors and reversed 'T' symbols represent inhibition.
ICP10PK neuroprotection in MPP+ model of PD SQ Wales et al MPP+-induced toxicity, 8 but their contribution to cell death is still controversial. Some reports suggested that calpains act independently of the caspases in different apoptotic pathways, 42 whereas others concluded that they cooperate. 31 In the latter case, calpain activation was found to follow the activation of the caspases 43 or initiate it. 31 Calpain cleavage of caspases-9 and -3 was reported to attenuate or facilitate their activity during apoptosis, 44, 45 but more recent data suggested that calpains function in caspase-independent neuronal cell apoptosis. 6, 7, 22, 42 Our studies suggest that calpains, at least calpain I, are important in the death of dopaminergic neurons, through both mitochondrial dysfunction that is characterized by AIF release, and caspase-3 activation. They also demonstrate that ICP10PK inhibits calpain activation, thereby interfering with both of these cascades. ICP10PK overrides these death programs through activation of the PI3-K/Akt survival pathway that results in the upregulation and stabilization of Bcl-2 and Hsp70, both of which are known to protect from PD pathology. 6, 9 Though we acknowledge that in vitro models may not be clinically relevant, our findings suggest that ICP10PK has the distinct advantage over other previously considered gene therapy strategies in that it targets those components of the death regulatory network which seem to be important in the demise of dopaminergic neurons. In this context, it may be significant to point out that the physiopathology of PD was also associated with death programs that were not studied in the present series of experiments, including growth factor depletion (viz nerve growth factor, NGF), 46 activation of the JNK pathway, 35 and glial cell activation and production of proinflammatory cytokines (viz tumor-necrosis factor-a, and interleukin-1b), 46 all of which are also inhibited by ICP10PK. 11, 12, 14, 27 ICP10PK also upregulates XIAP, 12 which was also implicated in PD therapy. 35, 47 We conclude that ICP10PK has a broad-spectrum neuroprotective activity, which is characterized by remarkable functional redundancy associated with the activation of survival pathways that can inhibit multiple death programs and modulate neuron-glial cell cross talk. By targeting most of the death programs implicated in PD physiopathology, ICP10PK holds great promise as a PD gene therapy strategy that warrants further investigation in in vivo models.
Materials and methods
Cells and neuronal differentiation
The establishment, properties and differentiation patterns of the PC12 cells stably transfected with ICP10PK (PC47) or its kinase-negative mutant p139t (PC139) were previously described. 12 Briefly, 96-100% of the cells express the respective transgenes. Expression is equally robust, but only ICP10 retains kinase activity. Similar expression and kinase activity were seen throughout the study interval (passages 27-48). Transgene expression did not alter NGF-induced differentiation. Thus, PC139 and PC47 cells cultured (4 or 12 days) with NGF evidenced virtually identical neurite formation as PC12 cells studied in parallel, and there was no visible difference between the 4-and 12-day cultures. Neurite formation reflects differentiation, because MAP-2, which is an established marker of mature neurons, 48 was only expressed in cultures grown with NGF ( Supplementary  Figure 1) . Its levels were similar in PC12, PC139 and PC47 cells. The NGF-differentiated cells were largely nondividing, as determined by 5-bromo-2 0 -deoxyuridine incorporation (see Supplementary Figure 1 ). In the present experiments, the cells were cultured (4 days) with NGF (100 ng ml À1 , 2.5S; Roche, Indianapolis, IN, USA) and treated with MPP+ (Sigma, St Louis, MO, USA) used at a concentration of 5 mM unless otherwise stated. MPP+ stocks were made fresh for each experiment.
Antibodies and reagents
The generation and specificity of the rabbit polyclonal antibody to ICP10, which recognizes an epitope that is retained by both ICP10PK and p139t, was described previously. 12, 15, 16, 49 The following antibodies were purchased and used according to manufacturer's instructions. Antibodies to activated caspase-3 (caspase-3p20), phosphorylated (activated) Akt (pAkt), Akt and Bcl-2 were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies to AIF, TH, actin, GAPDH, Hsp70, Bax and calpain were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Fluorescentconjugated secondary antibodies were anti-mouse-FITC (BD Biosciences, San Jose, CA, USA), anti-goat Alexa Fluor 546, anti-rabbit-Alexa Fluor 488, -Alexa Fluor 546 or -Alexa Fluor 350 (Invitrogen-Molecular Probes, Eugene, OR, USA). The MEK inhibitor U0126 was purchased from Promega (Madison, WI, USA), and used at a final concentration of 20 mM. The PI3-K inhibitor, LY294002, and the calpain inhibitor calpeptin were purchased from Calbiochem (San Diego, CA, USA), and both were used at a final concentration of 50 mM. The mitochondrion-selective dye MitoTracker Red 580, the uptake of which is independent of mitochondrial membrane potential, was purchased from Invitrogen (Eugene, OR, USA) and used to visualize mitochondria, as per manufacturer's instructions. Phosphorothioate antisense (TCCACACCGGAACATTTCGGCGA) and sense (TCGCCGAAATGTTCCGGTGTGGA) oligonucleotides specific for AIF were synthesized by the Biopolymer/Genomics Core Facility at the University of Maryland School of Medicine, reconstituted in sterile water and used at a final concentration of 10 mM.
TUNEL
The In Situ Cell Death Detection Kit (Roche) was used according to the manufacturer's instructions. Cells were counted in five randomly chosen microscopic fields (at least 250 cells), and results are expressed as percent TUNEL + (apoptotic) cells±s.e.m., as previously described. 12, 15, 16 Immunoblotting Cell extraction and immunoblotting was performed as previously described. 12, 15, 16 Protein concentrations were determined by the bicinchoninic assay (Pierce, Rockford, IL, USA) and 100 mg protein samples were resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. For nuclear and cytoplasmic separation, fractions were obtained by resuspending cells in 50 mM Tris-Hcl buffer (pH 8.0) with 50 mM NaCl, 1% NP-40, 1 mM dithiothreitol and protease inhibitors on ICP10PK neuroprotection in MPP+ model of PD SQ Wales et al ice, followed by centrifugation (7000 g; 1 min). The supernatant is the cytoplasmic fraction. The nuclear pellet was resuspended in the same buffer but with 450 mM NaCl (10 min, 4 1C) and sonicated until in solution. In this case, 50 mg protein was loaded onto the lanes. Quantitation was by densitometric scanning with the Bio-Rad GS-700 imaging densitometer (Bio-Rad, Hercules, CA, USA) and results are expressed as densitometric units.
Viruses
The construction and properties of the HSV-2 mutants DRR and DPK were previously described. 13 Immunofluorescent staining 
Statistical analyses
Analysis of variance was performed with Sigma Stat version 3.1 for Windows (Systat Software, Point Richmond, CA, USA).
